• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Bio-Rad’s Restructuring and Digital PCR Momentum Might Change The Case For Investing In BIO

    Simply Wall St·08/13/2026 16:33:42
    Listen to the news
    • In early August 2026, Bio-Rad Laboratories reported second-quarter 2026 results showing sales of US$651.0 million, higher net income of US$371.4 million, and reaffirmed full-year non-GAAP guidance while outlining expectations for flat third-quarter revenue and a mid-single-digit percentage ramp into the fourth quarter.
    • The company also highlighted strong digital PCR growth above 20%, a return to growth in clinical diagnostics, and a new restructuring program targeting US$30 million to US$35 million in cost savings by the end of 2027 to support innovation and operating efficiency.
    • We’ll now explore how Bio-Rad’s cost-saving restructuring program and strengthening digital PCR trends may influence its existing investment narrative.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    Bio-Rad Laboratories Investment Narrative Recap

    To own Bio Rad today, you need to believe its core life science and clinical diagnostics franchises can translate innovation in areas like digital PCR into durable earnings, despite uneven demand and margin pressure. The latest results, with flat year over year sales but higher net income and reaffirmed guidance, support a steady near term outlook, while the key short term catalyst remains execution on digital PCR growth. The main risk, in my view, is still margin pressure if instrument demand stays soft.

    The most relevant recent announcement here is Bio Rad’s new restructuring program targeting US$30 million to US$35 million in cost savings by the end of 2027. Against a backdrop of modest revenue trends and past gross margin compression, this plan directly intersects with the margin risk and could help support profitability if end markets remain sluggish. How effectively management delivers on these savings will likely influence how investors weigh the digital PCR growth story against ongoing operational headwinds.

    Yet behind the promising digital PCR growth, there is still a real risk investors should be aware of around sustained gross margin pressure and...

    Read the full narrative on Bio-Rad Laboratories (it's free!)

    Bio-Rad Laboratories' narrative projects $2.7 billion revenue and $226.1 million earnings by 2029. This requires 1.2% yearly revenue growth and a $57.3 million earnings increase from $168.8 million today.

    Uncover how Bio-Rad Laboratories' forecasts yield a $293.00 fair value, a 19% downside to its current price.

    Exploring Other Perspectives

    BIO 1-Year Stock Price Chart
    BIO 1-Year Stock Price Chart

    Before this update, the most cautious analysts expected roughly flat revenue at about US$2.6 billion and earnings of around US$232 million by 2029, which is far more pessimistic than narratives that lean on digital PCR momentum and cost savings, so you should weigh how this new information might shift both the bearish case and your own view.

    Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth as much as $301.66!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 1 important warning sign that could impact your investment decision.
    • Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

    Seeking Other Investments?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.